Navigation Links
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Date:10/3/2007

Broadens late-stage product development portfolio building on lead product

candidate EcoNail in Phase 2 trial for onychomycosis

WELLESLEY HILLS, Mass., Oct. 3 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced that it has exercised the option it acquired in July, 2007 to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation.

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials and that fits our strategic focus and complements our lead product candidate, EcoNail(R) for treatment of nail fungus," stated Robert J. DeLuccia, President and CEO of MacroChem. "Both drugs would treat diseases of the foot predominantly treated by the same prescribing specialists, namely podiatrists. Both EcoNail and pexiganan are potentially of interest to a larger number of physician specialists and primary care physicians. MacroChem would ultimately be seeking a partner for marketing to those groups while retaining rights to market to selected physician specialists."

In clinical trials previously conducted by Genaera, over 1000 human subjects were exposed to pexiganan without safety concerns, including 418 patients who received pexiganan in two Phase 3 clinical trials submitted in a New Drug Application to the U.S. Food and Drug Administration (FDA) in 1998. The primary clinical endpoint of one of the two Phase 3 trials was judged by the FDA to have been achieved. The other Phase 3 clinical trial, which did not meet its specified endpoint, provided strong supportive data indicative of the clinical benefit of pexiganan. At that time, difficulties with Chemistry Manufacturing & Controls (CMC) and an FDA request for one additional controlled trial precluded approval. Ma
'/>"/>

SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
(Date:12/22/2014)... Dec. 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) ... vaccine, has been filed and is now open and ... the Department of Health and Human Services (HHS), through ... "We are extremely pleased to have the IND ... represents a significant milestone in our company,s partnership with ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... Robert Mazzacavallo has joined Veridiam as the company,s Chief ... of high-precision, fabricated assemblies and metal components, primarily serving ... aerospace and general industrial markets. , Before joining Veridiam, ... Camas, WA. At C-Tech, Bob worked closely with ...
... 3 Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... will host a conference call on Thursday, November 12, ... financial and operating performance for the first quarter ended ... product development and marketing activities. , Corgenix invites all ...
Cached Medicine Technology:Veridiam Names Robert Mazzacavallo New CFO 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Med, the leader in inpatient,practice management information systems, ... new milestones. Record sales and product,deployments in the ... closer to,the 4,000 user mark, which the company ... the company expects to reach 500 million dollars ...
... Comprising the "infrastructure" for the Information Age, cyberinfrastructure ... resources is essential for future research advancement and ... Fran Berman, director of the San Diego Supercomputer Center ... the case for investment in cyberinfrastructure as part of ...
... mark therapy -- is now available in Houston, Texas. ... carbon dioxide to improve the skin,s appearance. , ... ... http://www.carboxytherapymd.com/ [Carboxytherapy], a cosmetic skin rejuvenation method and ...
... July 29 Care Investment Trust Inc.,(NYSE: CRE ... 2008,financial results before the market opens on Tuesday, August ... call on Tuesday, August 12, 2008, at,11:00 a.m. Eastern ... may,be accessed live by dialing 800-240-7305 or by visiting ...
... Jean-Yves Naouri, Executive,Vice President (Group Operations) and member ... to oversee Publicis Healthcare,Communications Group (PHCG) following John ... of Publicis Groupe, declared: "PHCG has,built over time ... and his teams are doing an excellent job. ...
... as an active mother of two in Potomac, Md., ... baseball games and her daughter,s horseback-riding lessons with numerous ... Add to this Spaeth,s thriving home business turned ... - which she founded with her mother. ...
Cached Medicine News:Health News:Ingenious Med Continues Record Customer Growth and Approaches Key Milestones 2Health News:Ingenious Med Continues Record Customer Growth and Approaches Key Milestones 3Health News:San Diego Supercomputer Center director urges academia to make cyberinfrastructure 'real' 2Health News:New Stretch Mark and Skin Rejuvenation Treatment Introduced to Houston by Dr. Zaniewski-Singh 2Health News:Jean-Yves Naouri to Oversee Publicis Healthcare Communications Group (PHCG) 2Health News:Jean-Yves Naouri to Oversee Publicis Healthcare Communications Group (PHCG) 3Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 2Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 3Health News:Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in 4
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Medicine Products: